This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration (NCT03869684), a randomized phase 2 study. The primary outcome is Change in Best-corrected Visual Acuity (BCVA) : Study Eye.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT03869684 |
| Phase | Phase 2 |
| Condition | Age-related Macular Degeneration |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Enrollment | 13 |
| Arms in the primary outcome | 3 |
| Lead sponsor | Senju Pharmaceutical Co., Ltd. |
| Results posted | Yes |
2. Clinical Question
Population
The trial concerned patients with age-related macular degeneration. Its brief summary describes development of MT-0814 for exudative, or wet, AMD. The primary outcome population was the full-analysis set: participants randomly assigned to masked study drug who received at least one dose. The registry record does not report enough eligibility detail to characterize the enrolled participants further.
Intervention
Participants were assigned to MT-0814 at a low or high dose. The low-dose arm description says MT-0814 plus placebo. Dose amounts, administration route, and detailed treatment schedules are not reported in the registry record.
Comparator
The comparator was placebo. The study was randomized, quadruple-masked, parallel-group, and placebo-controlled. The registry record does not provide further details about how masking was implemented or maintained.
Primary question
The primary question was how best-corrected visual acuity in the study eye changed from baseline to Week 12 in the assigned groups. Visual acuity was recorded as the number of letters read correctly on the ETDRS scale. The registry reports least-squares mean changes with 95% confidence intervals for placebo, low-dose MT-0814, and high-dose MT-0814. It does not report a comparative treatment estimate or a statistical test of differences between groups.
3. Trial Design
This was a phase 2, randomized, quadruple-masked, parallel-group, placebo-controlled study. The official title describes a multicenter trial. The registry lists enrollment of 13 participants and the status as terminated. The recorded start date is 2019-02-25, and the primary completion date is 2020-03-25. The reason for termination and the circumstances leading to it are not reported in the registry record.
The listed arms were placebo, MT-0814 low dose, and MT-0814 high dose. The arm counts for the primary outcome were 3 for placebo, 5 for low-dose MT-0814, and 5 for high-dose MT-0814. The low-dose arm description specifies MT-0814 plus placebo; descriptions of the other arms do not provide further treatment details. Dose amounts, route, frequency, treatment duration, and any dose-escalation procedure are not reported in the registry record.
The primary endpoint was change in best-corrected visual acuity in the study eye, with the timeframe stated as baseline and Week 12. A secondary outcome was change in central subfield thickness in the study eye. Although the record lists two outcome measures, it does not post a numerical result for the secondary outcome in the available results. The registry record does not report a protocol sample-size justification, planned treatment contrasts, or the full statistical analysis plan. These omissions limit what can be established about the intended design beyond the characteristics explicitly recorded.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Placebo | MT-0814 Low Dose | MT-0814 High Dose |
|---|---|---|---|
| STARTED | 3 | 5 | 5 |
| COMPLETED | 1 | 2 | 2 |
| NOT COMPLETED | 2 | 3 | 3 |
Reasons for not completing this period:
| Reason | Placebo | MT-0814 Low Dose | MT-0814 High Dose |
|---|---|---|---|
| Adverse Event | 0 | 3 | 1 |
| Withdrawal by Subject | 1 | 0 | 0 |
| Lost to Follow-up | 1 | 0 | 0 |
| Study prematurely terminated by sponsor | 0 | 0 | 2 |
Analysis population for the primary outcome, as defined in the registry: Full-analysis set (FAS): The FAS consisted of all participants who were randomly assigned to receive double-masked study drug and who have received at least 1 dose of study drug. All analyses using the FAS grouped participants according to randomly assigned treatment.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Placebo | MT-0814 Low Dose | MT-0814 High Dose | Total |
|---|---|---|---|---|---|
| Participants analysed | 3 | 5 | 5 | 13 | |
| Age, Categorical: <=18 years | Participants | 0 | 0 | 0 | 0 |
| Age, Categorical: Between 18 and 65 years | Participants | 2 | 1 | 0 | 3 |
| Age, Categorical: >=65 years | Participants | 1 | 4 | 5 | 10 |
| Sex: Female, Male: Female | Participants | 2 | 4 | 2 | 8 |
| Sex: Female, Male: Male | Participants | 1 | 1 | 3 | 5 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 3 | 5 | 5 | 13 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized: American Indian or Alaska Native | Participants | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized: Asian | Participants | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized: Black or African American | Participants | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized: Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized: Whte | Participants | 3 | 5 | 5 | 13 |
| Race/Ethnicity, Customized: Other | Participants | 0 | 0 | 0 | 0 |
| Region of Enrollment: United States | participants | 3 | 5 | 5 | 13 |
| Best-corrected Visual Acuity (BCVA) : Study eye | Letters | 62.0 (SD 10.82) | 66.8 (SD 7.98) | 71.2 (SD 4.15) | 67.4 (SD 7.74) |
| Central Subfield Thickness (CSFT) : Study eye | mm | 0.2990 (SD 0.04015) | 0.3748 (SD 0.05981) | 0.3954 (SD 0.08581) | 0.3652 (SD 0.07369) |
6. Primary Endpoint
The registry lists the primary outcome as Change in Best-corrected Visual Acuity (BCVA) : Study Eye, measured over Baseline and Week 12.
| Element | Registry entry |
|---|---|
| Result type | Least Squares Mean |
| Measure of spread | 95% Confidence Interval |
| Unit | letters |
| Endpoint classification | Continuous Endpoint |
The primary endpoint was change from baseline in best-corrected visual acuity (BCVA) in the study eye, assessed at Week 12. BCVA was measured with an eye chart and expressed as the number of letters read correctly on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, which ranges from 0 to 100 letters. The record notes that a lower number of letters read correctly indicates worse vision.
Visual acuity is a functional measure: it records performance on a standardized letter-reading task rather than a structural feature of the eye. Using change from baseline focuses the outcome on how the measured score moved during the study, while retaining the participant's starting score as the reference. The record describes least-squares mean change and 95% confidence intervals for this continuous outcome.
The study eye was selected from eyes meeting the inclusion criteria. If both eyes met the criteria, the eye with lower BCVA at screening was selected; if the qualifying eyes had identical BCVA, the investigator selected the study eye. The registry record does not report the underlying screening scores or additional details about endpoint assessment procedures.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry reports least-squares mean change in study-eye BCVA for each arm. The placebo estimate was 0.4 letters, with a 95% confidence interval from -7.7 to 8.5. The MT-0814 low-dose estimate was 0.3 letters, with a 95% confidence interval from -5.6 to 6.1. The MT-0814 high-dose estimate was 0.1 letters, with a 95% confidence interval from -6.1 to 6.3. These are within-arm change estimates, not estimates of the difference between an MT-0814 arm and placebo.
The intervals are broad relative to the point estimates. They include values on either side of zero, so the posted results are compatible with changes in either direction for each group. The intervals therefore do not pin down the direction or magnitude of change precisely. Their overlap also does not establish that the groups are equivalent: a direct comparison requires an estimate of the between-group contrast and its uncertainty, neither of which is posted.
The endpoint counts were 3 in placebo and 5 in each MT-0814 arm. With these small arm counts, each participant's observations can have substantial influence on a group estimate, and uncertainty can remain large. The registry does not report individual participant outcomes, distributions, or an analysis of treatment differences, so the group summaries cannot show how consistent responses were within an arm.
The record lists the study as terminated. That status is important context, but the reason for termination is not reported in the registry record. It cannot by itself establish why enrollment or follow-up ended, whether the planned enrollment was reached, or whether the termination was related to efficacy, safety, logistics, or another consideration.
No comparative p-value or treatment-effect confidence interval is posted. The available estimates describe the observed arm-level changes; they do not support a firm conclusion about a treatment contrast. In particular, the near-zero point estimates should not be interpreted as proof of no effect, just as the intervals should not be treated as evidence that every value within them is equally plausible. The findings are imprecise summaries from a small, terminated trial, and the registry record does not report enough information to resolve the uncertainty.
9. Statistical Methods Explained
The primary outcome is continuous: it is a change in the number of letters read correctly. The registry reports a least-squares mean for each arm and a 95% confidence interval. It does not report the underlying model specification, covariates, handling of repeated measurements, or a comparative analysis. The interpretation therefore needs to stay with the posted arm estimates and avoid treating them as adjusted treatment contrasts.
What does a least-squares mean represent?
In general, a least-squares mean is a model-based estimate of an outcome mean. Depending on the statistical model, it may account for specified covariates or other design features. The exact adjustment and model matter: an adjusted mean is not necessarily the same as the raw arithmetic mean. The registry labels the reported estimates as least-squares means but does not report the model or adjustment details. It is therefore not possible to determine which factors, if any, were included or to reproduce the calculation from the registry record.
How should the confidence intervals be read?
In general, a confidence interval conveys uncertainty around an estimate under the assumptions of the analysis that produced it. A narrower interval indicates greater precision than a wider interval on the same measurement scale. The reported intervals quantify uncertainty for each arm's mean change; they are not confidence intervals for differences between arms. Because the registry does not report the model details, the assumptions underlying these intervals cannot be assessed from the posted results alone. Their width makes clear that the arm-level changes are not estimated precisely.
A confidence interval that includes zero does not prove that the true change is zero. It indicates that the reported analysis has not localized the estimate to one side of zero at the interval's stated confidence level. Conversely, an interval that includes values on both sides of zero does not mean that all values in the interval have the same probability. It describes uncertainty according to the method used, rather than a probability distribution for the fixed underlying effect.
Why is a treatment contrast needed?
For a randomized trial, the treatment question usually concerns the difference in outcome between assigned groups. An arm's change from baseline alone combines any treatment-associated change with other influences, including natural variation and changes that may also occur under placebo. A direct contrast compares the groups on the chosen outcome scale and should be accompanied by an uncertainty estimate. The registry reports no such contrast for this endpoint. The listed estimates cannot be subtracted to create a sponsor analysis, and no unadjusted recalculation is posted for this comparison.
Comparing whether separate arm confidence intervals overlap is not a substitute for estimating a contrast. The uncertainty of a difference depends on the estimates' uncertainty and their relationship, as well as on the analysis method. The interval for each arm answers a different question from the interval for a treatment difference. No between-group test or p-value is reported in the registry record.
What does the small arm count imply?
Small samples generally provide limited information about outcome variability and make estimates sensitive to individual observations. They tend to produce less precise estimates, although the exact precision also depends on variability and the analysis. The registry gives the primary outcome counts by arm but does not report a standard deviation or another separate dispersion statistic. A confidence interval is available for each mean, but further distributional details cannot be inferred from it. These limitations make it especially important not to overread small differences among the point estimates.
Over-dispersion is a general concern when observed variability exceeds what a statistical model assumes; it can make standard errors and confidence intervals too optimistic if the model does not accommodate the extra variability. That concept is not evidence that over-dispersion occurred in this trial. The registry does not report diagnostics or enough model detail to assess it. Likewise, the continuous nature of BCVA change does not establish that any particular distributional model was used.
What can planning calculations tell a reader?
In general, a planning illustration based on an observed effect asks what sample size might be needed under stated assumptions to detect an effect of a chosen size. It is not an observed power calculation and does not establish the power that the trial actually had. Estimates from a small study can be unstable, so using an observed effect for planning can produce an uncertain illustration. The registry record does not report the trial's own sample-size justification. Any planning assumptions or illustrations should therefore be kept separate from evidence about the observed results and from claims about the original protocol.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists a primary outcome of change in study-eye BCVA and a secondary outcome of change in central subfield thickness in the study eye. It does not report the testing hierarchy, whether either outcome had multiple time points or comparisons, or how multiplicity was handled. A multiplicity adjustment or strategy is therefore not reported in the registry record. Without that information, the nominal interpretation of any hypothetical collection of tests cannot be established; no comparative p-values are posted for the primary outcome in any case.
The primary outcome population is described as the full-analysis set. It included participants randomly assigned to masked study drug who received at least one dose, with analyses grouped according to randomly assigned treatment. The registry reports outcome counts of 3, 5, and 5 across placebo, low-dose MT-0814, and high-dose MT-0814. The record does not report whether every randomized participant received a dose, how many participants were excluded from the full-analysis set, or whether other analysis populations were used.
Missing-outcome handling is not reported in the registry record. There is no stated method for incomplete Week 12 observations, withdrawals, or missing baseline values, and no reported sensitivity analysis addressing missing data. The effect of missingness on the arm estimates cannot be evaluated from the posted summaries alone. The registry's termination status makes transparent accounting of follow-up and missing outcomes particularly relevant, but the reason for termination and those details are not reported.
The registry also does not report whether the primary analysis followed an intention-to-treat principle, beyond the stated full-analysis-set definition and assignment-based grouping. No protocol deviations, exclusions, or imputation procedures are described. These omissions do not establish that any particular method was or was not used; they mean that the analysis choices cannot be verified from the registry record.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Placebo | 0 | 3 | 0.0% |
| MT-0814 Low Dose | 0 | 5 | 0.0% |
| MT-0814 High Dose | 2 | 5 | 40.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Placebo | 0 of 3 |
| MT-0814 Low Dose | 0 of 5 |
| MT-0814 High Dose | 0 of 5 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Placebo | 3 of 3 |
| MT-0814 Low Dose | 5 of 5 |
| MT-0814 High Dose | 3 of 5 |
Most frequent serious adverse event terms
| Event term | Organ system | Placebo | MT-0814 Low Dose | MT-0814 High Dose |
|---|---|---|---|---|
| Hepatic enzyme increased | Investigations | 0 of 3 | 0 of 5 | 1 of 5 |
| Liver function test increased | Investigations | 0 of 3 | 0 of 5 | 1 of 5 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Placebo | MT-0814 Low Dose | MT-0814 High Dose |
|---|---|---|---|---|
| Fatigue | General disorders | 1 of 3 | 1 of 5 | 1 of 5 |
| Nausea | Gastrointestinal disorders | 1 of 3 | 0 of 5 | 1 of 5 |
| Gamma-glutamyltransferase increased | Investigations | 1 of 3 | 0 of 5 | 1 of 5 |
| Neovascular age-related macular degneration | Eye disorders | 0 of 3 | 1 of 5 | 1 of 5 |
| Alanine aminotransferase increased | Investigations | 0 of 3 | 1 of 5 | 1 of 5 |
| Aspartate aminotransferase increased | Investigations | 0 of 3 | 1 of 5 | 1 of 5 |
| Migraine | Nervous system disorders | 1 of 3 | 0 of 5 | 0 of 5 |
| Cataract nuclear | Eye disorders | 1 of 3 | 0 of 5 | 0 of 5 |
| Eye pain | Eye disorders | 1 of 3 | 0 of 5 | 0 of 5 |
| Headache | Nervous system disorders | 1 of 3 | 0 of 5 | 0 of 5 |
Serious events with the highest arm-level rate: hepatic enzyme increased (20.0%), liver function test increased (20.0%).
The serious adverse event figures describe participants affected in each arm, alongside the number at risk. The registry reports 0 of 3 participants affected in the placebo arm, 0 of 5 in the MT-0814 low-dose arm, and 2 of 5 in the MT-0814 high-dose arm. It reports no deaths in any arm. These are counts from this trial; they do not establish a comparative safety effect, particularly given the small arm counts.
The registry lists “Hepatic enzyme increased” and “Liver function test increased” as top serious-event terms, each at 20.0%. The record does not specify the arm attribution for these terms in the posted term listing, nor does it provide enough detail to connect each term to an individual participant or event. The two descriptions may concern related measurements, but their relationship is not reported in the registry record and should not be assumed.
Counts of participants affected are not the same as counts of events: a participant may experience more than one event, and the registry record does not provide the event-level detail needed to distinguish these quantities. These figures also do not describe event timing, duration, severity beyond the serious classification, or causal attribution. The absence of reported serious events in an arm does not demonstrate that no risk exists; it means none were recorded as affecting participants in that arm in the posted results.
12. What the Result Does, and Does Not, Mean
The registry results describe small arm-level changes in study-eye BCVA over the baseline-to-Week-12 timeframe. The reported least-squares means were 0.4 letters for placebo, 0.3 letters for low-dose MT-0814, and 0.1 letters for high-dose MT-0814. Each estimate has a 95% confidence interval that spans values below and above zero. The intervals are broad, so the estimates are imprecise.
These values do not answer whether MT-0814 changed BCVA more or less than placebo. A within-arm change is not a randomized between-arm treatment effect, and no treatment contrast is posted. The results also do not establish equivalence or absence of an effect. A conclusion of equivalence would require a defined margin and an analysis designed to assess it; neither is reported in the registry record.
The trial enrolled 13 participants and is listed as terminated. The registry does not state why it was terminated or whether the planned enrollment was completed. This context, combined with the small arm counts and lack of a reported comparative analysis, limits how much can be concluded from the numerical estimates. The values should be read as descriptive results with substantial uncertainty, not as a definitive test of the treatment question.
The record also lists change in central subfield thickness as a secondary outcome, but a numerical result for it is not reported in the available results. Safety counts are posted, including serious events in the high-dose arm and no deaths, but the small numbers and limited event detail do not resolve comparative risk. Overall, the registry record leaves important questions about efficacy, safety, missing data, and analysis methods unanswered. Those absences are limits on interpretation, not evidence for a particular explanation of the trial's findings or termination.
13. Why This Trial Matters Statistically
This trial illustrates the distinction between describing change within groups and estimating a randomized treatment effect. A mean change for each arm can show how the measured outcome moved from baseline, but a treatment comparison requires a between-group contrast. The registry reports the former and does not report the latter. That distinction is essential when interpreting placebo-controlled trials: a change in an active-treatment arm cannot be attributed to treatment merely because it occurred during treatment.
The results also show why uncertainty deserves attention alongside point estimates. The arm-level BCVA estimates are close to zero, but their confidence intervals are broad and include values in either direction. A point estimate alone can look more decisive than the evidence warrants. With small arm counts, precision is limited, and the available summaries do not reveal the range of individual participant outcomes.
Trial status and reporting completeness matter statistically as well. The record marks the study as terminated but does not report the reason, missing-data handling, multiplicity strategy, or model details. Without those details, readers cannot fully assess how the planned analysis relates to the posted estimates or whether incomplete follow-up affected them. This is a reminder that registry interpretation depends not only on the numerical results but also on the transparency of the analysis and conduct.
Finally, a planning illustration based on an observed effect should not be mistaken for evidence that a study had adequate or inadequate power. Planning calculations depend on assumptions and are separate from observed results. The trial's own sample-size justification is not reported in the registry record. Keeping design information, observed estimates, and planning exercises distinct helps prevent an imprecise small trial from being overinterpreted in either direction.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The primary outcome estimates come from a small number of participants: 3 in placebo and 5 in each MT-0814 arm. The resulting confidence intervals are broad. The registry does not provide individual observations or a separate dispersion statistic, which limits assessment of variability and sensitivity to influential observations.
The registry reports arm-level least-squares means but does not describe the model, adjustment variables, covariance structure, or missing-data method. It also does not post a direct comparison of either MT-0814 dose with placebo. The reported summaries therefore do not establish the size or precision of a treatment contrast. The stated endpoint timeframe is baseline and Week 12; other outcome time points are not reported for the primary result.
The record lists the trial as terminated, but the reason is not reported in the registry record. It also does not state whether the planned enrollment was achieved, provide a detailed account of participant flow, or describe follow-up completeness. The protocol's sample-size justification, multiplicity plan, and fuller statistical analysis plan are not reported. The low-dose arm is described as MT-0814 plus placebo, while dose amounts and treatment administration details are not reported.
The secondary outcome is named, but its numerical result is not reported in the available results. Safety reporting includes counts and serious-event terms, but lacks event-level timing and arm attribution for the listed terms. These limitations do not show that unreported analyses or procedures were absent; they restrict what can be assessed from the registry record.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration — NCT03869684.
- Registry record last updated 2021-04-20; status last verified 2021-03.
- Results first posted 2021-04-20.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry record describes a randomized, quadruple-masked, parallel-group, placebo-controlled phase 2 study of MT-0814 in age-related macular degeneration. Enrollment was 13, and the study status is terminated. The recorded start date is 2019-02-25 and the primary completion date is 2020-03-25.
The primary outcome was change in study-eye BCVA from baseline to Week 12. Least-squares mean changes were 0.4 letters for placebo, 0.3 letters for low-dose MT-0814, and 0.1 letters for high-dose MT-0814, with broad 95% confidence intervals. No comparative estimate or test is reported. A secondary outcome concerned central subfield thickness, but its numerical result is not reported in the available results.
Serious adverse events affected 0 of 3 placebo participants, 0 of 5 low-dose participants, and 2 of 5 high-dose participants; no deaths were reported. Interpretation is limited by the small arm counts and by missing registry entries on the model, missing-data methods, multiplicity, sample-size rationale, and reason for termination.